Перспективы искусственного интеллекта в доклинических и клинических исследованиях

Standard

Перспективы искусственного интеллекта в доклинических и клинических исследованиях. / Свечкарева, И. Р.; Гусев, А. В.; Колбин, Алексей Сергеевич.

в: КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ, Том 34, № 1, 01.02.2025, стр. 14-19.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

BibTeX

@article{a3826d42f086468091b34e22a3142dda,

title = "Перспективы искусственного интеллекта в доклинических и клинических исследованиях",

abstract = "The objective of this systematic literature review was to identify and analyse studies using or integrating artificial intelligence (AI) in clinical pharmacology. The available data suggest that the use of AI and machine learning may facilitate drug discovery and development and may reduce costs and partly eliminate the need in preclinical and/or clinical trials.",

author = "Свечкарева, {И. Р.} and Гусев, {А. В.} and Колбин, {Алексей Сергеевич}",

year = "2025",

month = feb,

day = "1",

doi = "10.32756/0869-5490-2025-1-14-19",

language = "русский",

volume = "34",

pages = "14--19",

journal = "КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ",

issn = "0869-5490",

publisher = "Фармапресс",

number = "1",

}

RIS

TY - JOUR

T1 - Перспективы искусственного интеллекта в доклинических и клинических исследованиях

AU - Свечкарева, И. Р.

AU - Гусев, А. В.

AU - Колбин, Алексей Сергеевич

PY - 2025/2/1

Y1 - 2025/2/1

N2 - The objective of this systematic literature review was to identify and analyse studies using or integrating artificial intelligence (AI) in clinical pharmacology. The available data suggest that the use of AI and machine learning may facilitate drug discovery and development and may reduce costs and partly eliminate the need in preclinical and/or clinical trials.

AB - The objective of this systematic literature review was to identify and analyse studies using or integrating artificial intelligence (AI) in clinical pharmacology. The available data suggest that the use of AI and machine learning may facilitate drug discovery and development and may reduce costs and partly eliminate the need in preclinical and/or clinical trials.

UR - https://www.mendeley.com/catalogue/620d0d78-7c1b-36af-8a16-a7837acfa61f/

U2 - 10.32756/0869-5490-2025-1-14-19

DO - 10.32756/0869-5490-2025-1-14-19

M3 - статья

VL - 34

SP - 14

EP - 19

JO - КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ

JF - КЛИНИЧЕСКАЯ ФАРМАКОЛОГИЯ И ТЕРАПИЯ

SN - 0869-5490

IS - 1

ER -

ID: 133653778